International Journal of Pharmaceutical Sciences and Research, Journal Year: 2023, Volume and Issue: 14(9)

Published: Sept. 1, 2023

Parkinson's disease (PD) is the second most prevalent type of neurodegenerative disorder and a chronic, progressive condition.In current investigation, we used rotenone (ROT)-developing rat model PD to assess neuroprotective efficacy ethanolic Withania somnifera root extract (EWSR) in comparison known neuroprotectants i.e., Doxycycline (Doxy), ellagic acid (EA) individually combination (EWSR-Doxy-EA).Male Wistar rats were given ROT at dose 2.5 mg/kg body weight daily for 4 weeks develop invivo model.Once confirmed, treated with individual next 5 kept under observation 7 days reversal PD.ROT administration has altered behavioural parameters (Cognitive, motor dysfunction, sniffing, grooming, raring, crossing, etc.) neurotransmitter profile (Acetylcholine, epinephrine, nor-epinephrine, dopamine, glutamate aspartate) rats.The ameliorated deleterious effects restored cognitive control by rectifying levels neurotransmitters which are responsible functions.EWSR protective was significantly better that (Doxy EA) EWSR increased when combined other neuroprotectants.Based on study observations, it can be inferred good agent act as potential alternative therapeutic approach or drugs treating diseases.INTRODUCTION: progressive, late-onset condition marked development fibrillar cytoplasmic inclusions containing α-synuclein ubiquitin relatively selective nigrostriatal dopaminergic loss.

Language: Английский